Is Wellbutrin an Antipsychotic or Antidepressant?

Wellbutrin is an antidepressant, not an antipsychotic. Its generic name is bupropion, and it has been prescribed for depression since the late 1980s. The confusion is understandable, though, because bupropion affects dopamine, a brain chemical closely associated with antipsychotic medications. That shared connection to dopamine is where the mix-up starts, and it leads to some genuinely interesting questions about what this drug does and does not do.

How Wellbutrin Works

Most antidepressants target serotonin, either alone or alongside norepinephrine. Wellbutrin does neither. It blocks the reuptake of dopamine and norepinephrine, meaning it lets those two chemicals linger longer in the spaces between nerve cells.¹ It has essentially no effect on serotonin. That makes it unusual among antidepressants and is the main reason its side-effect profile looks so different from drugs like sertraline (Zoloft) or fluoxetine (Prozac).

Antipsychotics, by contrast, work in the opposite direction on dopamine. They block dopamine receptors, dialing down dopamine signaling. Wellbutrin enhances dopamine activity; antipsychotics dampen it. The two drug classes are doing fundamentally different things to the same chemical system. This is a crucial distinction, because boosting dopamine and blocking dopamine have very different clinical consequences.

What Wellbutrin Is Approved For

The FDA has approved bupropion for three uses, depending on the formulation. The extended-release version (Wellbutrin XL) is approved for major depressive disorder and for preventing seasonal affective disorder. A separate sustained-release formulation, marketed as Zyban, is approved specifically for smoking cessation.² No formulation of bupropion carries an indication for any psychotic disorder, bipolar mania, or any condition that antipsychotics treat.

As an antidepressant, bupropion performs about as well as SSRIs and SNRIs in head-to-head trials. Studies have found it comparable to fluoxetine, escitalopram, and venlafaxine on standard depression rating scales.³ A separate review echoed this, concluding that bupropion’s effectiveness matched most other common antidepressants while offering a more favorable tolerability profile.⁴

Why Dopamine Creates the Confusion

When people hear that a psychiatric medication affects dopamine, they often think of antipsychotics, because for decades the dopamine system was the central target in treating conditions like schizophrenia. That association is so deeply ingrained that any drug touching dopamine can get mentally filed in the antipsychotic category. But the direction matters enormously. Antipsychotics reduce dopamine signaling at certain receptors. Bupropion increases the amount of dopamine available. If anything, bupropion does the pharmacological opposite of what a typical antipsychotic does.

There is also a naming issue. Bupropion is sometimes described as an “atypical antidepressant” because it does not fit neatly into the SSRI or SNRI categories. The word “atypical” also appears in “atypical antipsychotic,” a term for newer drugs like quetiapine or aripiprazole. Two completely unrelated uses of the same adjective can create a false impression of kinship between the drug classes.

A Side-Effect Profile Unlike Other Antidepressants

One of bupropion’s biggest practical selling points is what it does not cause. Because it skips serotonin entirely, it avoids the side effects most people associate with antidepressants. There is strong evidence that SSRIs cause sexual dysfunction and that bupropion causes substantially less of it.⁵ The same research found that long-term SSRI use can lead to weight gain, while long-term bupropion tends to produce a small weight loss. Sedation is also less of an issue compared to older tricyclic antidepressants.³

A large survey of people taking antidepressants found that about 46% reported emotional blunting, the flat, muted feeling some patients describe as “not sad but not anything.” That rate did not vary much across drug types, but it appeared less frequent with bupropion.⁶ For people whose main complaint about antidepressants is feeling emotionally numb, this can make bupropion worth discussing with a prescriber.

These tolerability advantages are a major reason bupropion gets prescribed so frequently despite being mechanistically different from the rest of the antidepressant lineup. For someone who has tried an SSRI and stopped because of sexual side effects or weight gain, bupropion often becomes the next conversation.

Smoking Cessation and How It Helps

Bupropion’s role in smoking cessation is its second most recognized use, and it adds another layer to the “what kind of drug is this?” question. People sometimes assume a drug that helps you quit smoking must be something other than an antidepressant. In reality, the same dopamine and norepinephrine activity that lifts mood also eases nicotine withdrawal. Bupropion appears to mimic some of nicotine’s effects on those systems, reducing cravings and withdrawal irritability. It also blocks nicotinic acetylcholine receptors, which may reduce the rewarding feeling of smoking if someone does relapse.⁷

In clinical trials, bupropion helped roughly one in five smokers achieve abstinence, a modest but real improvement over placebo.⁸ It is not the most effective smoking cessation drug available, but it remains widely used, particularly for people who cannot tolerate other options or who also have depression.

Off-Label Uses

Bupropion gets prescribed off-label for a number of conditions, most commonly ADHD in adults. A controlled trial found that adults with ADHD who took bupropion showed a 42% reduction in symptoms after six weeks, compared to 24% on placebo, and over three-quarters of the bupropion group met response criteria.⁹ A Cochrane review looking across several trials found that bupropion reduced ADHD severity and increased the proportion of people who improved, though the overall quality of the evidence was low.¹⁰ Bupropion is not a first-line ADHD treatment, and it does not work as well as stimulants for most people, but it is a reasonable alternative when stimulants are not an option.

Bupropion is also one half of a combination weight-loss medication. When paired with naltrexone, it is marketed as Contrave and targets appetite-regulating pathways in the brain.¹¹ This use takes advantage of bupropion’s dopamine and norepinephrine effects on energy and appetite rather than its antidepressant properties, though the underlying pharmacology is the same.

Can Wellbutrin Cause Psychosis?

Here is where the relationship between bupropion and antipsychotics gets genuinely complicated. Because bupropion increases dopamine activity, and excess dopamine signaling is linked to psychotic symptoms, the drug can in rare cases trigger or worsen psychosis. A systematic review of the literature found some evidence that bupropion can cause or worsen psychotic symptoms in certain people, particularly at higher doses and in those with preexisting psychotic symptoms or substance use disorders.¹² Case reports describe patients developing frank psychosis on bupropion that resolved when an antipsychotic was added.¹³

This does not mean bupropion is dangerous for the general population. The risk is concentrated in people who already have a vulnerability to psychosis. For most patients taking bupropion for depression or smoking cessation, psychotic symptoms are not a realistic concern. But the fact that bupropion can, in susceptible individuals, push dopamine activity high enough to provoke psychosis is a useful illustration of why it is not an antipsychotic. It is doing the opposite of what an antipsychotic would do, and in vulnerable brains, that opposite action can become a problem.

Using Bupropion Alongside Antipsychotics

Despite the psychosis risk in vulnerable people, bupropion sometimes gets added to an antipsychotic regimen deliberately. People with schizophrenia often experience “negative symptoms,” a cluster of problems including emotional flatness, social withdrawal, and lack of motivation that antipsychotics do not address well. Since bupropion boosts dopamine and norepinephrine, researchers have explored whether it can help fill that gap.

The results are mixed. A small case series reported that adding bupropion to existing antipsychotic treatment improved negative symptoms in all three patients studied.¹⁴ However, a controlled trial comparing bupropion to placebo in patients with schizophrenia found no significant improvement in negative symptoms.¹⁵ The evidence here is thin and contradictory, and bupropion is not a standard treatment for negative symptoms.

Where bupropion has a clearer role in this population is smoking cessation. People with schizophrenia smoke at very high rates, and quitting is difficult. A subgroup analysis from a large safety trial (EAGLES) found that bupropion increased the odds of abstinence in smokers with schizophrenia spectrum disorders without causing a significant increase in neuropsychiatric side effects compared to placebo.¹⁶ A broader analysis from the same trial, covering people with psychotic, anxiety, and mood disorders, confirmed that neither bupropion nor varenicline significantly increased neuropsychiatric adverse events relative to placebo across any diagnostic group.¹⁷ That finding was reassuring after years of concern about whether bupropion was safe for people with psychiatric conditions.

Drug Interactions to Know About

Bupropion is a potent inhibitor of a liver enzyme called CYP2D6, which breaks down a long list of other medications. If you take bupropion alongside a drug that relies on CYP2D6 for metabolism, the other drug can build up in your system to higher-than-expected levels.¹⁸ This includes certain antipsychotics, beta-blockers, some opioids, and other antidepressants.

The effect is dose-dependent. At higher bupropion doses, the inhibition is stronger. One clinical study found that half of patients on high-dose bupropion were functionally converted to the equivalent of poor metabolizers for CYP2D6, meaning their bodies processed CYP2D6-dependent drugs as slowly as someone genetically lacking the enzyme.¹⁹ This matters practically because prescribers need to adjust doses of co-prescribed medications when starting or stopping bupropion, especially at 300 mg/day or above. It is one of the more significant drug interactions in psychiatry, and not every clinician thinks to check for it.

Seizure Risk and Misuse

Bupropion was originally brought to market in 1985 but pulled the following year because of seizure reports.²⁰ When researchers figured out the seizures were dose-related, bupropion returned with lower recommended doses and a cap on daily intake. At standard doses, the seizure risk is low and comparable to other antidepressants. The risk climbs sharply at supratherapeutic doses and in people with conditions that already lower the seizure threshold, such as bulimia nervosa or alcohol withdrawal. The drug carries a formal contraindication for people with seizure disorders and current or prior bulimia or anorexia.

Misuse is uncommon but documented. Because bupropion affects dopamine, it can produce stimulant-like effects when taken in ways that bypass its extended-release coating. Crushing and snorting the pills, for example, delivers a rapid dopamine surge that the delayed-release formulation is specifically designed to prevent.²¹ Reports of bupropion misuse have surfaced in correctional facilities and substance-use treatment settings. In one extreme case, a patient with bulimia escalated bupropion XR to several thousand milligrams per day and suffered grand mal seizures.²² At prescribed doses taken orally as directed, the abuse potential is low. The risk lives almost entirely in non-oral routes and extreme dose escalation.

When Bupropion Gets Paired With Other Psychiatric Drugs

Because bupropion occupies a unique pharmacological space, it is commonly combined with other antidepressants rather than used alone. A prescriber might pair an SSRI (for serotonin) with bupropion (for dopamine and norepinephrine) to cover more of the neurochemical territory involved in depression. This combination can also offset SSRI-induced sexual side effects, since bupropion’s dopamine activity tends to work in the opposite direction of the SSRI’s dampening effects on sexual function.

In bipolar disorder, bupropion sometimes gets added to a mood stabilizer for depressive episodes. It has been considered a lower-risk option than some other antidepressants for triggering manic switches, though the evidence is not definitive. The case reports of bupropion-induced psychosis mostly involved people with known psychotic vulnerability or very high doses, so the risk profile looks different in a patient already stabilized on a mood stabilizer or antipsychotic.

The practical takeaway is that bupropion plays well with many other psychiatric medications, and its distinct mechanism makes it a natural complement rather than a redundancy. Understanding that it is an antidepressant, not an antipsychotic, helps make sense of why it gets combined with so many different drug classes. It fills a gap that serotonin-focused drugs leave open, and it does so with a tolerability profile that most patients find easier to live with than the alternatives.